Afficher la notice abrégée

The economic burden of preventable adverse drug reactions: a systematic review of observational studies

dc.rights.licenseopenen_US
dc.contributor.authorFORMICA, D.
dc.contributor.authorSULTANA, J.
dc.contributor.authorCUTRONEO, P. M.
dc.contributor.authorLUCCHESI, S.
dc.contributor.authorANGELICA, R.
dc.contributor.authorCRISAFULLI, S.
dc.contributor.authorINGRASCIOTTA, Y.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSALVO, Francesco
dc.contributor.authorSPINA, E.
dc.contributor.authorTRIFIRO, G.
dc.date.accessioned2020-11-10T08:33:42Z
dc.date.available2020-11-10T08:33:42Z
dc.date.issued2018-07
dc.identifier.issn1744-764X (Electronic) 1474-0338 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/12174
dc.description.abstractEnINTRODUCTION: Adverse drug reactions (ADRs) are an important cause of morbidity and mortality worldwide. They are associated with healthcare costs due to hospital admissions or prolonged length of stay (LOS), as well as additional interventions. The aim of this study was to conduct a systematic review of observational studies to evaluate the economic impact of preventable ADRs. Areas covered: Published observational research investigating the cost of preventable ADRs in Western countries (limited to the US and European countries). Expert opinion: Several reviews have been carried out in the field of the ADR epidemiology but fewer reviews have investigated the economic impact of ADRs, and at the time of writing, none has focused on preventable ADRs. The reason why future research should focus on the costs of preventable ADRs is that both the costs and the clinical outcomes are preventable, and as such, are a key point of public health policy action. Nevertheless, the present review highlights an important and sobering limitation of published research on the cost of preventable ADRs, of which the major limitation is the heterogeneity in methods and in reporting limit what can be known through a summarizing work of a systematic review.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enThe economic burden of preventable adverse drug reactions: a systematic review of observational studies
dc.title.alternativeExpert Opin Drug Safen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/14740338.2018.1491547en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29952667en_US
bordeaux.journalExpert Opinion on Drug Safetyen_US
bordeaux.page681-695en_US
bordeaux.volume17en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03194280
hal.version1
hal.date.transferred2021-04-10T01:43:59Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Expert%20Opinion%20on%20Drug%20Safety&rft.date=2018-07&rft.volume=17&rft.issue=7&rft.spage=681-695&rft.epage=681-695&rft.eissn=1744-764X%20(Electronic)%201474-0338%20(Linking)&rft.issn=1744-764X%20(Electronic)%201474-0338%20(Linking)&rft.au=FORMICA,%20D.&SULTANA,%20J.&CUTRONEO,%20P.%20M.&LUCCHESI,%20S.&ANGELICA,%20R.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée